Premium
Gd‐DOTA Conjugate of RGD as a Potential Tumor‐Targeting MRI Contrast Agent
Author(s) -
Park JiAe,
Lee JaeJun,
Jung JaeChang,
Yu DaeYeul,
Oh Chilhwan,
Ha Seunghan,
Kim TaeJeong,
Chang Yongmin
Publication year - 2008
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.200800529
Subject(s) - dota , conjugate , chemistry , pentapeptide repeat , mri contrast agent , cancer research , cytotoxicity , chelation , gadolinium , peptide , medicine , biochemistry , in vitro , mathematical analysis , mathematics , organic chemistry
Tumor recognition : Conjugation of 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid (DOTA) with the cyclic pentapeptide c(RGDYK) and subsequent complexation with GdCl 3 ⋅ 6 H 2 O afforded Gd‐DOTA‐RGD, which, although a single molecular entity, is an efficient, target‐specific MRI contrast agent for the α ν β 3 receptors in hepatocellular carcinoma in H‐ ras 12V transgenic mice. The compound displays very low cytotoxicity and might hence warrant further study for clinical usage.